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Editorial on the Research Topic
Challenges of Pharmacoeconomics in Global Health Arena
The pace of globalization has significantly accelerated since the end of the Cold War Era in 1989.
These changes profoundly affected health care systems worldwide (Jakovljevic et al., Jakovljevic
et al.). Health policy makers increasingly started facing new harsh challenges in their uneasy task
to provide universal health coverage and decent equity of access to medical services. Among the
most prominent demand-side issues are extended longevity joined with population aging (1), rise
of non-communicable diseases, and growing patient expectations (2). Supply-side causes are gains
in societal welfare and living standards, technological innovation in medicine and continuing rapid
urbanization in developing world regions (3). Successful insurance-based risk sharing agreements
made drug dispensing and medical service provision cheap or virtually free at the point of
consumption in most OECD and many middle-income countries. Coupled with massive build-up
of workforce capacities and strengthening of primary care and hospital networks, all these factors
contributed to the “supplier induced demand” phenomenon (4).
There is straightforward historical evidence of long-term growth in pharmaceutical and overall
health spending both in absolute and GDP% terms worldwide (5). The accumulated constraints
deriving from skyrocketing costs of care were felt in many areas of clinical medicine even among
the richest societies. Cardinal examples of expensive and hardly affordable therapeutic areas are
orphan drugs indicated to treat rare diseases and targeted biologicals used in autoimmune disorders
and cancer (Kamusheva et al.). Last but not least, is troubled and frequently denied access to
even essential generic pharmaceuticals still taking place in many nations (6). This appears to
be particularly the case among the world’s poor and underserved citizens residing in rural and
suburban areas of low- and middle-income countries (3). To a large extent, these difficulties are
worsened by lack of evidence-based resource allocation strategies and less sustainable financing
strategies (Pejcic).
This Research Topic has successfully attracted a variety of contributions tackling the core
challenges of medicines provision and medical care financing across the globe. Its target to reveal
some of the hidden underlying causes of uneven access to medicines was achieved to great extent. A
total of eleven articles have been published. Exceptional regional diversity covering national health
system issues ranging from Papua New Guinea to Brazil, Syria, Denmark, Finland, Bulgaria, Serbia,
Bosnia and Herzegovina, Croatia, Macedonia, Montenegro, Slovenia, and South Africa.
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A variety of methodological approaches was exploited
in these articles inclusive of epidemiological research,
perspectives, literature reviews, commentaries, and ultimately
two systematic reviews. Large part of these contributions focused
on sustainability of antibiotics supply in hospitals (Zwane
et al.) and clinical and economics consequences of irresponsible
prescribing and dispensing (Horvat et al.). Probably the most
prominent example, given the civil war related circumstances
is the contribution coming from Syria, describing how one of
the most developed pharmaceutical industries in MENA/Eastern
Mediterranean region came to drug shortages of essential
medicines (Jakovljevic et al.).
Japanese research was conducted on malaria diagnostics in
pediatric South-East Asian populations (Tsukahara et al.). The
Bulgarian group wrote an excellent review on the role of ethical
and legal considerations in biometric data usage (Deliversky
and Deliverska). Another piece coming from Balkan academic
centers dealt with prescribing policies on pharmaceuticals and
their affordability among chronic patients suffering from NCDs
(Pekez-Pavlisko et al.). Probably the two most ambitious pieces
were the two systematic reviews. The first one compiled
the evidence published in the Brazilian academic, industry
and governmental sectors output in interdisciplinary studies
surrounding health economics (Decimoni et al.) while the second
one, compiled by one of the Topic editors, did a bibliographic
synthesis of global health economics publishing output in
quantitative terms (Jakovljevic and Pejcic). Given the entire scale
of contributions by solicited and unsolicited research groups
worldwide, Editors believe that the Research Topic has lived up
to its goal and achieved expectations filling some knowledge gaps
in the science of pharmacoeconomics.
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